Nycomed is keeping the pace in third quarter 2010

Nycomed's strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole.

Nycomed's strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole. Daxas? (roflumilast) has recently been launched in the first EU markets and further launches are underway over the coming months. To accelerate the expansion in China, one of the fastest growing pharma markets, Nycomed acquired the majority stake in Guangdong Techpool Bio-Pharma Co., Ltd.

The market introduction of Daxas? (roflumilast) in Europe is promising. Nycomed's US partner Forest Laboratories, Inc. (NYSE: FRX) has submitted a response to the US Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast (Daxas?). Nycomed and Forest expect a response from the FDA in the first quarter of 2011.

Pantoprazole sales